François Laliberté/LinkedIn
Aug 6, 2025, 12:52
RPTH Journal: Rivaroxaban vs Warfarin in PE with RV Dysfunction
RPTH Journal shared a new study on LinkedIn:
”Do clinical outcomes differ between patients treated with rivaroxaban vs warfarin for PE/RVD?
Rivaroxaban was more effective than warfarin without a significant increase in safety.”
Read the full article here.
Article: Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study
Authors: François Laliberté, Behnood Bikdeli, Veronica Ashton, Guillaume Germain, Julien Boudreau, Manasvi Sundar, Sean D. MacKnight, Brahim Bookhart, Dereck Wentworth, Shawn Murphy, Yichuan G. Hsieh, Gregory Piazza
Find the latest scientific advances featured in Hemostasis Today.
Behnood Bikdeli
Brahim Bookhart
Dereck Wentworth
François Laliberté
Gregory Piazza
Guillaume Germain
Health
Hematology
Hemostasis Today
Julien Boudreau
Manasvi Sundar
Medicine
PE
Pulmonary embolism
right ventricular dysfunction
Rivaroxaban
Rivaroxaban vs Warfarin
RPTH Journal
RVD
Sean D. MacKnight
Shawn Murphy
Veronica Ashton
Warfarin
Yichuan G. Hsieh
-
Nov 15, 2025, 12:24Thomas Reiser: Can AI Keep Up with Thrombosis Specialists?
-
Nov 15, 2025, 12:13Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
-
Nov 15, 2025, 09:32Tushar Pandey: Hounoured to Be Part of Hematocon 2025
-
Nov 15, 2025, 09:11Lisa Murphy invites You to Join Her at Stroke Foundation’s Run4Stroke Marathon
-
Nov 15, 2025, 08:56Ahmed Bennis on Potential Use of P2Y12 Inhibitors as Safer Alternative in Monotherapy
-
Nov 15, 2025, 08:39Marika Nöjd: Donating Blood is An Easy Way to Do Good!
-
Nov 15, 2025, 08:19Joseph Caprini Released His UIP 2025 Session on VTE Recurrence Risk
-
Nov 15, 2025, 07:14Paul Bolaji Invites You to ”Thrombolytic Therapy in Acute Stroke in African Patients” Seminar
-
Nov 15, 2025, 07:03Carla Goulart Peron Explores The Role of Technology and Collaboration in Global Stroke Action